Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of itscurrent intentions and future prospects, this release contains statements thatare forward looking, including statements related to the therapeutic andcommercial potential of PX-12; future clinical development plans; the detailsof clinical trials; and the anticipated future size of the market for PX-12.These forward-looking statements represent Oncothyreon's intentions, plans,expectations and beliefs and are based on its management's experience andassessment of historical and future trends and the application of keyassumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, includingrisks and uncertainties related to Oncothyreon's business and the generaleconomic environment. Many of these risks and uncertainties are beyondOncothyreon's control. These risks, uncertainties and other factors couldcause our actual results to differ materially from those projected inforward-looking statements. Risks, uncertainties, and assumptions includethose predicting the timing, duration and results of clinical trials, thetiming and results of regulatory reviews, and the safety and efficacy ofPX-12. There can be no guarantee that the results of earlier trials will bepredictive of either safety or efficacy in future trials. These and otherrisks and uncertainties are described in the reports and other documents filedby Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statementscontained herein are reasonable, it can give no assurance that itsexpectations are correct. All forward-looking statements are expresslyqualified in their entirety by this cautionary statement. For a detaileddescription of the risks and uncertainties associated with Oncothyreon, youare encouraged to review the official corporate documents filed by OncothyreonInc. with the securities regulators in United States and Canada with the SECand on SEDAR. Oncothyreon is under no obligation to (and expressly disclaimsany such obligation to) update or alter its forward-looking statements whetheras a result of new information, future events, or otherwise.

Additional Information

Additional information relating to Oncothyreon can be found on U.S. EDGARat www.sec.gov and on SEDAR at www.sedar.com.

SOURCE Oncothyreon Inc.